Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in esophageal adenocarcinoma

Journal of Gastrointestinal Surgery

Volumn 16, Issue 5, 2012, Pages 956-966

  Prins, M J D ^a   Verhage, R J J ^a   Ten Kate, F J W ^a   van Hillegersberg, R ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adenocarcinoma; COX 2; Esophageal cancer; Esophagectomy; Survival; VEGF

Indexed keywords

CYCLOOXYGENASE 2; ISOENZYME; TUMOR MARKER; VASCULOTROPIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; EVALUATION; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; CONFIDENCE INTERVALS; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84865329253     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-011-1814-1     Document Type: Article

References (52)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010;60:277-300.
2. Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N.Engl.J.Med. 2006;355:11-20.
3. Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, ten Kate FJW, Obertop H, Tilanus HW, Van Lanschot JJ. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann.Surg. 2007;246:992-1000.
4. van Meerten E, Muller K, Tilanus HW, Siersema PD, Eijkenboom WM, van Dekken H, Tran TC, van der Gaast A. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br.J.Cancer 2006;94:1389-1394.
5. Aklilu M, Ilson DH. Targeted agents and esophageal cancer-the next step? Semin.Radiat.Oncol. 2007;17:62-69.
6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
7. Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist. 2005;10:590-601.
8. Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, Shima K, Hazra A, Chan AT, Dehari R, Giovannucci EL, Fuchs CS. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin. Cancer Res. 2008;14:8221-8227.
9. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, Kim HS, Nam DK, Lee KB, Kim HC. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin. Cancer Res. 2000;6: 519-525.
10. Matsubayashi H, Infante JR, Winter J, Klein AP, Schulick R, Hruban R, Visvanathan K, Goggins M. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol. Ther. 2007;6:1569-1575.
11. Wu YC, Su LJ, Wang HW, Jeff Lin CF, Hsu WH, Chou TY, Huang CY, Lu CL, Hsueh CT. Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 adversely affects the postoperative survival in non-small cell lung cancer. J.Thorac. Oncol. 2010;5:1167-1174.
12. Barisik NO, Keser SH, Gul AE, Sensu S, Kandemir NO, Kucuk HF, Gumus M, Karadayi N. The value of COX-2 expression in the prognostic parameters of invasive ductal carcinoma of the breast. Med. Oncol. 2010;28:703-708.
13. Boone J, van Hillegersberg R, Offerhaus GJ, van Diest PJ, Borel Rinkes IHM, ten Kate FJW. Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Dis. Esophagus. 2009;22:496-504.
14. Buskens CJ, Van Rees BP, Sivula A, Reitsma JB, Haglund C, Bosma PJ, Offerhaus GJ, Van Lanschot JJ, Ristimaki A. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002;122:1800-1807.
15. Kleespies A, Bruns CJ, Jauch KW. Clinical significance of VEGFA, -C and -D expression in esophageal malignancies. Onkologie. 2005;28:281-288.
16. Donnem T, Al-Shibli K, Andersen S, Al-Saad S, Busund LT, Bremnes RM. Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer 2010;116:4318-4325.
17. Patard JJ, Rioux-Leclercq N, Masson D, Zerrouki S, Jouan F, Collet N, Dubourg C, Lobel B, Denis M, Fergelot P. Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br. J. Cancer 2009;101:1417-1424.
18. Saad RS, El-Gohary Y, Memari E, Liu YL, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum. Pathol. 2005;36:955-961.
19. Wu Y, Jin M, Xu H, Shimin Z, He S, Wang L, Zhang Y. Clinicopathologic significance of HIF-1alpha, CXCR4, and VEGF expression in colon cancer. Clin. Dev. Immunol. 2010;2010
20. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306-1311.
21. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000;19:19-27.
22. Tuynman JB, Buskens CJ, Kemper K, ten Kate FJW, Offerhaus GJ, Richel DJ, Van Lanschot JJ. Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann. Surg. 2005;242:840-9.
23. von Rahden BH, Stein HJ, Puhringer F, Koch I, Langer R, Piontek G, Siewert JR, Hofler H, Sarbia M. Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res. 2005;65:5038-5044.
24. Verhage RJ, Zandvoort HJ, ten Kate FJ, van Hillegersberg R. How to define a positive circumferential resection margin in T3 adenocarcinoma of the esophagus. Am. J. Surg. Pathol. 2011;35:919-926.
25. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual (7th edition). 2010
26. Heeren P, Plukker J, van Dullemen H, Nap R, Hollema H. Prognostic role of cyclooxygenase-2 expression in esophageal carcinoma. Cancer Lett. 2005;225:283-289.
27. Bhandari P, Bateman AC, Mehta RL, Stacey BS, Johnson P, Cree IA, Di NF, Patel P. Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus. BMC.Cancer 2006;6:134.
28. Takatori H, Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Sasaki K, Tamotsu K, Owaki T, Ishigami S, Aikou T. Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. Eur. J. Surg. Oncol. 2008;34:397-402.
29. Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997;79:206-213.
30. Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin. Cancer Res. 2000;6:1161-1168.
31. Ogata Y, Fujita H, Yamana H, Sueyoshi S, Shirouzu K. Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: long-term follow-up study. World J. Surg. 2003;27:584-589.
32. Couvelard A, Paraf F, Gratio V, Scoazec JY, Henin D, Degott C, Flejou JF. Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J.Pathol. 2000;192:14-18.
33. Ahn MJ, Jang SJ, Park YW, Choi JH, Oh HS, Lee CB, Paik HK, Park CK. Clinical prognostic values of vascular endothelial growth factor, microvessel density,and p53 expression in esophageal carcinomas. J. Korean Med. Sci. 2002;17:201-207.
34. Rosa AR, Schirmer CC, Gurski RR, Meurer L, Edelweiss MI, Kruel CD. Prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus. Dis. Esophagus. 2003;16:112-118.
35. Lu CL, Ji Y, Ge D, Guo J, Ding JY. The expression of CXCR4 and its relationship with matrix metalloproteinase-9/vascular endothelial growth factor in esophageal squamous cell cancer. Dis. Esophagus. 2011;24:283-290.
36. Vallbohmer D, Peters JH, Kuramochi H, Oh D, Yang D, Shimizu D, DeMeester SR, Hagen JA, Chandrasoma PT, Danenberg KD, Danenberg PV, DeMeester TR. Molecular determinants in targeted therapy for esophageal adenocarcinoma. Arch. Surg. 2006;141:476-481.
37. Yoshikawa R, Fujiwara Y, Koishi K, Kojima S, Matsumoto T, Yanagi H, Yamamura T, Hashimoto-Tamaoki T, Nishigami T, Tsujimura T. Cyclooxygenase-2 expression after preoperative chemoradiotherapy correlates with more frequent esophageal cancer recurrence. World J. Gastroenterol. 2007;13:2283-2288.
38. Mobius C, Stein HJ, Spiess C, Becker I, Feith M, Theisen J, Gais P, Jutting U, Siewert JR. COX2 expression, angiogenesis, proliferation and survival in Barrett's cancer. Eur. J. Surg. Oncol. 2005;31:755-759.
39. Kitadai Y, Haruma K, Tokutomi T, Tanaka S, Sumii K, Carvalho M, Kuwabara M, Yoshida K, Hirai T, Kajiyama G, Tahara E. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin. Cancer Res. 1998;4:2195-2200.
40. Uchida S, Shimada Y, Watanabe G, Tanaka H, Shibagaki I, Miyahara T, Ishigami S, Imamura M. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br. J. Cancer 1998;77:1704-1709.
41. Sato F, Shimada Y, Watanabe G, Uchida S, Makino T, Imamura M. Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer. Br. J. Cancer 1999;80:1366-1372.
42. Mukherjee T, Kumar A, Mathur M, Chattopadhyay TK, Ralhan R. Ets-1 and VEGF expression correlates with tumor angiogenesis, lymph node metastasis, and patient survival in esophageal squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2003;129:430-436.
43. Millikan KW, Mall JW, Myers JA, Hollinger EF, Doolas A, Saclarides TJ. Do angiogenesis and growth factor expression predict prognosis of esophageal cancer? Am. Surg. 2000;66:401-405.
44. Pufe T, Harde V, Petersen W, Goldring MB, Tillmann B, Mentlein R. Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in immortalized chondrocytes. J. Pathol. 2004;202:367-374.
45. Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimaki A, Turpeenniemi-Hujanen T. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res. Treat. 2005;89:215-220.
46. Sivula A, Buskens CJ, Van Rees BP, Haglund C, Offerhaus GJ, Van Lanschot JJ, Ristimaki A. Prognostic role of cyclooxygenase- 2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus. Int. J. Cancer 2005;116:903-908.
47. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J. Clin. Oncol. 2006;24:5201-5206.
48. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson AB3. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J. Clin. Oncol. 2010;28:2947-2951.
49. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J. Clin. Oncol. 2011;29:868-874.
50. Dawson SJ, Michael M, Biagi J, Foo KF, Jefford M, Ngan SY, Leong T, Hui A, Milner AD, Thomas RJ, Zalcberg JR. A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs 2007;25:123-129.
51. Govindan R, McLeod H, Mantravadi P, Fineberg N, Helft P, Kesler K, Hanna N, Stoner C, Ansari R, Fox E. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncology (Williston.Park) 2004;18:18-21.
52. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N.Engl.J.Med. 2005;352:1071-1080.